This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
NEW YORK (Reuters) - Out-of-favor U.S. industrial shares will get a chance to win over investors in the coming days as the companies report quarterly results and address concerns about escalating global trade tensions.
HON GEC MTSI GE HON BOE GNE CSX UTX UAL BA
General Electric (NYSE:GE) has recently become a story of one shoe after another dropping. The bounce that GE stock received after its removal from the Dow Jones Industrial Average appears to have run its course. Now, as the Boston-based conglomerate prepares to announce earnings, unwelcome surprises with GE Capital have come to light. This could explain why GE stock is so low. The earnings report should give more insight on whether GE continues on the road to recovery, or if GE Capital forces more shoes to drop.
GE GEC HON GNE UTX MMM
The April-June quarter of 2018 was plagued with worries, arising from the escalation of the trade war between the United States and other foreign nations, especially China. Though tariffs were imposed on the import of several goods for protecting the interest of U.S. domestic industries, it made many companies deal with higher raw material costs. Despite these issues, the strengthening global economy and the strong growth potential of the United States, along with favorable changes in its tax policy, have been well received by the markets.
HON GEC GE HON GNE
General Electric Company (GE - Free Report) is scheduled to report second-quarter 2018 results on Jul 20, before the market opens. The company’s Aviation segment is likely to benefit from rising global air travel while Renewable Energy is anticipated to enjoy growth in unit orders. In terms of corporate revenues, GE Aviation is one of the largest business units of the company — accounting for 24.8% of revenues in first-quarter 2018.
HON GEC GE MTSI HON GNE UTX
It has been a bumpy few months for investors this summer. Worries about trade tension between the U.S. and China took many sectors lower despite strong economic data from the U.S. Many have started prepping their portfolios for a downturn should President Donald Trump drag the U.S. into a full-fledged trade war with Beijing.
HD HON HON MU GM.WS.A GM.WS.B GM.WS.C NYTAB GM INTC GM.WSB
Honeywell International Inc. (HON - Free Report) is slated to report second-quarter 2018 results on Jul 20, before the market opens. The company pulled off an average positive earnings surprise of 1.49% over the preceding four quarters. Notably, its adjusted earnings of $1.95 per share outpaced the Zacks Consensus Estimate of $1.89 in the last reported quarter. Our proven model shows that Honeywell’s earnings will likely beat estimates in the to-be-reported quarter as well.
HON HON ATKR UTX ETN
General Electric Company (GE - Free Report) is scheduled to report second-quarter 2018 results on Jul 20, before market open. The company’s GE Power segment might feel the heat from difficult macroeconomic conditions. In terms of corporate revenues, GE Power is the largest business unit of the company — accounting for 25.2% of revenues in first-quarter 2018. Segment’s Q1 Performance, Estimates GE Power’s performance in first-quarter 2018 was weak on a year-over-year basis, with revenues down 7%, primarily due to the lower demand for turbines.
HON GEC GE MTSI HON GNE UTX
General Electric Company (GE - Free Report) is scheduled to report second-quarter 2018 results on Jul 20, before the market opens. This industrial conglomerate’s financial performance in the last four quarters was mixed, having recorded better-than-expected results in two and lagging estimates in the other two. The company’s average earnings surprise was a positive 3.27%. In the last reported quarter, the company’s earnings of 16 cents per share surpassed the Zacks Consensus Estimate of 11 cents by 45.
HON BHI HD GEC GE WAB HON GGG BHGE GNE
As an investment sector, the Internet of Things, or IoT, is a no-brainer. Increasingly, our consumer devices no longer have a specific function or operation; rather, they’re part of an integrated, digital ecosystem that responds to variable requests. This movement will only increase in volume and engagement, but picking the right IoT stock can be a challenge.
ADT FIT HON MU GRMN AAPL ADI EMR JCI INTC NTGR
Danaher Corporation (DHR - Free Report) is slated to report second-quarter 2018 results on Jul 19, before the market opens. The company pulled off an average positive earnings surprise of 4.09% over the preceding four quarters. Notably, Danaher’s first-quarter 2018 adjusted earnings of 99 cents per share outpaced the Zacks Consensus Estimate of 93 cents. Let’s see how things are shaping up prior to this announcement.
HON ALGN HON UTX DHR
Earnings reporting season is upon us, with a few of the major banks kicking it off last Friday. But with this season comes high expectations, as the Nasdaq and S&P 500 have risen recently to near all-time highs. This earnings season will be driven by some of the biggest companies in the United States, but they have to hit their targets first if the markets want to keep up their momentum.
HON BAC SLB PM GE GEC MS.PRE MS.PRF NFLX MS.PRG MS.PRA BAC MS.PRI HON MS.PRK TRI GNE SCL SLB MS EBAY
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
KMI.WS ECOR PLNT KMI.PRA PKG AEP NINE ADT GE COF-P GILD TMUS PDYPF SYF XERS JNJ VZ MSFT ADS KZR NNN EIDX FB RF.PRB AVRO RF.PRA HOPE NFLX AXP EHC BAC COF-D SEAS COF-C COF-F KR KS IIIV PNFP AAPL DDOC AEP.PRA SJM INPAP SIX JPM GNE WRK LGEJY KMRFZ DE 39IB KMX COF.WS RF UAL WMT CFIN LGEAF IP AMZN MGTA NTRS HON KMI CIWV GM.WS.A GM.WS.B HCSG GM.WS.C KMR CVB VLKAY LGEIY EBAY EPRT STT SLB BAC DFS LGEPF STM BBY BX BK STM LTXB LGLD SLB GM.WSB FOXA CLW COF.PRG COF.PRH PM STT.PRC STT.PRE NTRSP STT.PRD STT.PRG AUTL COF.PRP DLPH SWKS GS SWK TRTX GM PII COF.PRC COF.PRD DIS NEE COF.PRF IBM MOR F GEC C CMCSA COF FUN FUL CFG HBAN NEE.PRI XEL NEE.PRJ TGT BLK S PPG T NEE.PRC NEE.PRQ NEE.PRR SNE DPZ
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
HON THLEY VSAT HON ENT ISAT GOGO THLEF HO DAL ENTWW
The first half of 2018 is already over, so it is time to look back at how our portfolio performed, the purchases we made and to check our income growth.
SOJA LMT GIS XOM O.PRF TWX OPRF CVS ABT NKE HON AAPL ABBV DIS ABT VTR HON SO GILD O MA TWC RB CMI TGT V AFL PEP JNJ CVX DG MSFT SBUX ABBV QCOM
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to HON / Honeywell International, Inc. on message board site Silicon Investor.
as of ET